Literature DB >> 8732586

Schizophrenia and Alzheimer's disease: clinical and pathophysiologic analogies.

K E White1, J L Cummings.   

Abstract

Psychotic symptoms are prominent in schizophrenia and a frequent neuropsychiatric manifestation of Alzheimer's disease (AD), occurring in approximately 50% of patients affected. The shared psychiatric symptoms suggest common cerebral pathophysiologies. Radiologic and pathologic findings indicate a predilection toward limbic involvement, with structural and atrophic changes of the medical temporal region predominating in both disorders. Neurochemical alterations affecting the dopaminergic/cholinergic axis appear to be central to both schizophrenia and AD. The basic pathologies of the two disorders are different, but they have similarities in the pattern of regional brain dysfunction, biochemical dysfunction, and symptomatology. We represent a selective review of these similarities. Insights drawn from these observations enrich the understanding of each disorder.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8732586     DOI: 10.1016/s0010-440x(96)90035-8

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  13 in total

Review 1.  Cholinesterase inhibitors for behavioral disturbance in dementia.

Authors:  E J Daly; W E Falk; P Brown
Journal:  Curr Psychiatry Rep       Date:  2001-06       Impact factor: 5.285

2.  Mass spectrometry "sensor" for in vivo acetylcholine monitoring.

Authors:  Peng Song; Neil D Hershey; Omar S Mabrouk; Thomas R Slaney; Robert T Kennedy
Journal:  Anal Chem       Date:  2012-05-24       Impact factor: 6.986

3.  Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial.

Authors:  Oliver Freudenreich; Lawrence Herz; Thilo Deckersbach; A Eden Evins; David C Henderson; Corinne Cather; Donald C Goff
Journal:  Psychopharmacology (Berl)       Date:  2005-10-14       Impact factor: 4.530

4.  Proteomic analysis of eccrine sweat: implications for the discovery of schizophrenia biomarker proteins.

Authors:  Michelle M Raiszadeh; Mark M Ross; Paul S Russo; Mary Ann Schaepper; Weidong Zhou; Jianghong Deng; Daniel Ng; April Dickson; Cindy Dickson; Monica Strom; Carolina Osorio; Thomas Soeprono; Julia D Wulfkuhle; Emanuel F Petricoin; Lance A Liotta; Wolff M Kirsch
Journal:  J Proteome Res       Date:  2012-02-27       Impact factor: 4.466

5.  Cholinergic effects on fear conditioning II: nicotinic and muscarinic modulations of atropine-induced disruption of the degraded contingency effect.

Authors:  Sebastien Carnicella; Laure Pain; Philippe Oberling
Journal:  Psychopharmacology (Berl)       Date:  2005-02-05       Impact factor: 4.530

6.  Genome-wide association of polygenic risk extremes for Alzheimer's disease in the UK Biobank.

Authors:  Catarina Gouveia; Elizabeth Gibbons; Nadia Dehghani; James Eapen; Rita Guerreiro; Jose Bras
Journal:  Sci Rep       Date:  2022-05-19       Impact factor: 4.996

7.  Increased striatal dopamine (D2/D3) receptor availability and delusions in Alzheimer disease.

Authors:  Suzanne Reeves; Richard Brown; Robert Howard; Paul Grasby
Journal:  Neurology       Date:  2009-02-10       Impact factor: 9.910

Review 8.  Repurposing of Anti-Diabetic Agents as a New Opportunity to Alleviate Cognitive Impairment in Neurodegenerative and Neuropsychiatric Disorders.

Authors:  Qian Chen; Ting Cao; NaNa Li; Cuirong Zeng; Shuangyang Zhang; Xiangxin Wu; Bikui Zhang; Hualin Cai
Journal:  Front Pharmacol       Date:  2021-05-24       Impact factor: 5.810

9.  Cognitive phenotype of psychotic symptoms in Alzheimer's disease: evidence for impaired visuoperceptual function in the misidentification subtype.

Authors:  Suzanne J Reeves; Chloe Clark-Papasavas; Rebecca L Gould; Dominic Ffytche; Robert J Howard
Journal:  Int J Geriatr Psychiatry       Date:  2015-03-24       Impact factor: 3.485

Review 10.  Transgenerational Interaction of Alzheimer's Disease with Schizophrenia through Amyloid Evolvability.

Authors:  Yoshiki Takamatsu; Gilbert Ho; Masaaki Waragai; Ryoko Wada; Shuei Sugama; Takato Takenouchi; Eliezer Masliah; Makoto Hashimoto
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.